Oncology · Medical Literature
[Correspondence] Perspective on proton beam therapy for oropharyngeal cancer – Authors' reply
Abstract
We thank Pietro De Luca and colleagues for their thoughtful letter and agree that surgical salvage after intensity-modulated proton therapy (IMPT) is an important and underexplored question.
Clinical relevance
In the context of the TORPEdO phase 3 trial comparing intensity-modulated proton therapy (IMPT) with intensity-modelled radiation therapy (IMRT) for oropharyngeal squamous cell carcinoma, what is the TORPEdO authors' perspective on the question of surgical salvage feasibility and outcomes following IMPT? __SNAPSHOT__ {"studyDesign":"Correspondence — Authors' reply to a published letter (not a primary research article). No original data are presented in this communication. The parent trial (TORPEdO) was a phase 3, open-label, randomised controlled trial (2:1 allocation, IMPT vs. IMRT).","setting":"Published in The Lancet; the parent TORPEdO trial was conducted across 20 UK National Health Service hospitals.","sampleSize":"Not applicable (correspondence reply). Parent TORPEdO trial: n=205 (IMPT: n=136; IMRT: n=69).","population":"Not applicable to this correspondence. Parent trial enrolled adults with newly diagnosed locally advanced oropharyngeal squamous cell carcinoma.","intervention":"Intensity-modulated proton therapy (IMPT) — as discussed in the correspondence context.","comparator":"Intensity-modulated radiation therapy (IMRT) — as discussed in the correspondence context.","primaryOutcome":"Not applicable (correspondence reply). The primary clinical question raised in this exchange pertains to surgical salvage outcomes following IMPT, which the authors acknowledge as 'an important and underexplored question.' No primary outcome data are reported in the correspondence.","followUp":"Not reported in this correspondence.","fundingSource":"Not reported in this correspondence. The parent TORPEdO trial was funded by Cancer Research UK (CRUK/18/010)."}
Key findings
This is a one-sentence authors' reply to a correspondence letter from Pietro De Luca and colleagues. The entirety of the retrievable abstract states only that the authors agree surgical salvage after IMPT is 'an important and underexplored question.' No quantitative data, effect sizes, p-values, confidence intervals, or outcome measurements of any kind are reported in this correspondence item. The full text of the reply was not publicly accessible at time of summary preparation. For reference, the parent TORPEdO trial reported co-primary endpoints at 12 months: (1) gastrostomy-tube dependence or severe weight loss ≥20%: 18% (IMPT) vs. 6% (IMRT), adjusted OR 2.80 (97.5% CI 0.75–10.41; p=0.079); (2) mean UW-QoL physical composite score: 78.3 (IMPT) vs. 77.1 (IMRT), difference 1.3 (97.5% CI –3.7 to 6.2; p=0.56). These parent trial figures are provided for context only and are not findings of this correspondence.
Practice implications
This authors' reply is a correspondence item — the shortest possible publication unit — and contains no original clinical data. It communicates only that the TORPEdO investigators (Thomson, Price, Tyler, Hall) acknowledge agreement with De Luca and colleagues that surgical salvage feasibility and outcomes after IMPT for oropharyngeal cancer represent an important, currently underexplored clinical domain. This is clinically relevant because proton therapy's distinct dose distribution and biological effects could theoretically alter tissue planes, wound healing, and resectability in the salvage setting compared with photon-based IMRT — a question that neither TORPEdO nor the contemporaneous Frank et al. US phase 3 trial was designed or powered to address. No conclusions regarding surgical salvage rates, complication profiles, or whether IMPT confers advantage or disadvantage in the salvage context can be drawn from this communication. CRITICAL LIMITATION: Only the abstract (one sentence) was available for this summary. The full text of the reply, which may contain additional commentary, nuance, or referenced data, was not accessible. Clinicians should obtain and read the full correspondence before drawing any inferences. __LIMITATIONS__ 1. Publication type: This is a correspondence reply — an opinion/discussion item, not a primary study. It generates no new evidence. 2. Extremely limited accessible content: Only a single-sentence abstract was available; the full text was inaccessible, making comprehensive analysis impossible. 3. No data reported: Surgical salvage outcomes after IMPT are acknowledged as underexplored but no data — incidence of recurrence, rates of attempted salvage surgery, complications, or survival post-salvage — are presented or cited in the accessible portion of this reply. 4. Selection and generalisability: Any future data on this question must account for the fact that most contemporary OPSCC, particularly HPV-associated disease, carries a favourable prognosis with low locoregional recurrence rates, making surgical salvage events relatively infrequent even in large trials. 5. Biological uncertainty: The relative biological effectiveness (RBE) assumptions for IMPT remain incompletely characterised and may influence tissue fibrosis and surgical field quality in ways not yet quantified clinically. 6. Conflict of interest: Not reported in this correspondence. The TORPEdO parent trial was independently funded by Cancer Research UK. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ This Lancet authors' reply contains no original data and consists solely of the TORPEdO investigators' acknowledgement that surgical salvage outcomes following IMPT for oropharyngeal cancer remain an important and underexplored clinical question. Clinicians should not alter practice based on this correspondence; the parent TORPEdO trial data, in which IMPT and IMRT showed broadly similar late toxicity, quality of life, local disease control, and overall survival outcomes, remain the primary evidentiary basis for treatment decisions. Dedicated prospective data on surgical salvage feasibility and outcomes after IMPT are currently lacking and needed.